Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

479
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
479
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

850
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
850

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations.

Expert review of endocrinology & metabolism·2026
Same author

The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B.

Scientific reports·2026
Same author

Redefinition of Fatty Liver Disease: Stigma or Fatphobia?

Journal of clinical and experimental hepatology·2026
Same author

Nationwide Trends of Noninvasive Tests for Liver Fibrosis in Japan Between 2014 and 2023.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Current and Future Landscape of Hepatocellular Carcinoma Treatment.

Oncology research·2026
Same author

Health inequity and the risk of MAFLD/MASLD.

Clinical nutrition ESPEN·2026
Same journal

Patient-Level Predictors of Procedural Success in Colon Capsule Endoscopy: A Systematic Review and Meta-Analysis.

Journal of gastroenterology and hepatology·2026
Same journal

Preventive Effect of Helicobacter pylori Treatment on Colorectal Cancer Incidence and Mortality.

Journal of gastroenterology and hepatology·2026
Same journal

Toward the Era of Precision Immunotherapy: The Clinical Landscape and Future Directions of mRNA Vaccines for the Treatment of Hepatocellular Carcinoma.

Journal of gastroenterology and hepatology·2026
Same journal

From Chronic Atrophic Gastritis to Low-Grade Intraepithelial Neoplasia: A Proteomic Study on the Sequential Progression of Gastric Precancerous Lesions.

Journal of gastroenterology and hepatology·2026
Same journal

Resource-Stratified Carbon-Adjusted Quality Indicators for Green Endoscopy.

Journal of gastroenterology and hepatology·2026
Same journal

Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.

Journal of gastroenterology and hepatology·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

654

Lean MASH: A High-Risk Subtype With Significant Cardiometabolic Burden

Yasser Fouad1, Alaa M Mostafa1, Ahmed Gomaa2

  • 1Department of Hepatology, Gastroenterology, and Endemic Medicine, Faculty of Medicine, Minia University, Minia, Egypt.

Journal of Gastroenterology and Hepatology
|November 30, 2025
PubMed
Summary

No abstract available in PubMed .

Keywords:
CKMMASHMASLDlean

More Related Videos

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K

Related Experiment Videos

Last Updated: Jan 9, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

654
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.4K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K